Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects - PubMed (original) (raw)
Clinical Trial
Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects
B N van Berckel et al. Neuropsychopharmacology. 1997 May.
Erratum in
- Neuropsychopharmacology 1997 Aug;17(2):116
Abstract
The effect of D-cycloserine, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, were assessed in a (neuroendocrine) challenge paradigm to to examine NMDA systems in male healthy volunteers, using a double-blind, placebo-controlled crossover design. Oral D-cycloserine (15, 50, and 150 mg) was readily absorbed and its plasma concentration increased dose-dependently. Behavioral and hormonal responses were measured for 240 minutes after administration of the drug. D-cycloserine was well tolerated and did not induce side-effects according to the Visual Analog Scales (VAS), the Brief Psychiatric Rating Scale (BPRS) and the Adverse Events Checklist (AEC) & codes. D-cycloserine failed to elicit a neuroendocrine response as evaluated by cortisol, prolactin, and luteinizing hormone (LH) plasma levels. The present result suggests that D-cycloserine can readily be administered to healthy volunteers but that, in the dosages used, neuroendocrine secretion fails to serve as a model for testing NMDA receptor function in humans.
Similar articles
- The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
van Berckel BN, Lipsch C, Gispen-de Wied C, Wynne HJ, Blankenstein MA, van Ree JM, Kahn RS. van Berckel BN, et al. Psychopharmacology (Berl). 1998 Jul;138(2):190-7. doi: 10.1007/s002130050662. Psychopharmacology (Berl). 1998. PMID: 9718289 Clinical Trial. - D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS. van Berckel BN, et al. Neuropsychopharmacology. 1999 Aug;21(2):203-10. doi: 10.1016/S0893-133X(99)00014-7. Neuropsychopharmacology. 1999. PMID: 10432468 Clinical Trial. - Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L, Petrakis IL, Pittman B, Gueorguieva R, D'Souza DC, Perry E, Limoncelli D, Krystal JH. Trevisan L, et al. Alcohol Clin Exp Res. 2008 Jan;32(1):36-42. doi: 10.1111/j.1530-0277.2007.00543.x. Epub 2007 Nov 20. Alcohol Clin Exp Res. 2008. PMID: 18028532 - D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
Schade S, Paulus W. Schade S, et al. Int J Neuropsychopharmacol. 2016 Apr 20;19(4):pyv102. doi: 10.1093/ijnp/pyv102. Print 2016 Apr. Int J Neuropsychopharmacol. 2016. PMID: 26364274 Free PMC article. Review. - Pharmacological treatments of cerebellar ataxia.
Ogawa M. Ogawa M. Cerebellum. 2004;3(2):107-11. doi: 10.1080/147342204100032331. Cerebellum. 2004. PMID: 15233578 Review.
Cited by
- Nervous system effects of antituberculosis therapy.
Kass JS, Shandera WX. Kass JS, et al. CNS Drugs. 2010 Aug;24(8):655-67. doi: 10.2165/11534340-000000000-00000. CNS Drugs. 2010. PMID: 20658798 Review. - Convergent Mechanisms Underlying Rapid Antidepressant Action.
Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD. Zanos P, et al. CNS Drugs. 2018 Mar;32(3):197-227. doi: 10.1007/s40263-018-0492-x. CNS Drugs. 2018. PMID: 29516301 Free PMC article. Review. - Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM. Liem-Moolenaar M, et al. Br J Clin Pharmacol. 2013 Jun;75(6):1455-67. doi: 10.1111/bcp.12015. Br J Clin Pharmacol. 2013. PMID: 23116363 Free PMC article. Clinical Trial. - Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
Sanacora G, Zarate CA, Krystal JH, Manji HK. Sanacora G, et al. Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462. Nat Rev Drug Discov. 2008. PMID: 18425072 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources